The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | ECHELON-2 trial updates and the role of transplant in CD30-positive PTCL
Swaminathan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, TX, shares some updates from the ECHELON-2 trial (NCT01777152) comparing the use of brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) with standard-of-care cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) for the treatment of patients with CD30-positive peripheral T-cell lymphoma (PTCL). Dr Iyer first highlights recent updates from this trial and then goes on to discuss the value of upfront stem cell transplantation in these patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE
